{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:46:04Z","timestamp":1793450764134,"version":"4.5.0"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"145","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2017,8,12]]},"published-print":{"date-parts":[[2017,9,30]]},"abstract":"<jats:p>Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting that treatment with specific drugs for IPF should be started as soon as diagnosis is made. This applies to any disease and particularly to IPF, which is marked by a 5-year survival comparable or even worse than many cancers. However, despite common sense and even worse, in spite of scientific data coming from clinical trials,<jats:italic>post hoc<\/jats:italic>analysis, long-term safety studies and real-life experiences, the question of when to start and when to stop treatment with antifibrotics is still debated. In IPF, particularly when the disease is diagnosed at an early stage, \u201cwait and watch\u201d behaviour is not rare to observe. This is largely due to the lack of awareness of both patients and clinicians regarding the progression of the disease and its prognosis. Another important issue is when treatment should be stopped. In general, there are two main reasons to stop a therapy: unbearable side-effects and\/or lack of efficacy. According to current (although preliminary) evidence, antifibrotic drugs should not be discontinued except for safety issues.<\/jats:p>","DOI":"10.1183\/16000617.0053-2017","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:10:21Z","timestamp":1507075821000},"page":"170053","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["When to start and when to stop antifibrotic therapies"],"prefix":"10.1183","volume":"26","author":[{"given":"Sebastiano Emanuele","family":"Torrisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"2024102403295654000_26.145.170053.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024102403295654000_26.145.170053.2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1580693"},{"key":"2024102403295654000_26.145.170053.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00015"},{"key":"2024102403295654000_26.145.170053.4","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003613"},{"key":"2024102403295654000_26.145.170053.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00077309"},{"key":"2024102403295654000_26.145.170053.6","unstructured":"National Cancer Institute . Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/ Date last updated: 2014. Date last accessed: April 2017."},{"key":"2024102403295654000_26.145.170053.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60052-4"},{"key":"2024102403295654000_26.145.170053.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2024102403295654000_26.145.170053.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201206-1010PP"},{"key":"2024102403295654000_26.145.170053.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202640"},{"key":"2024102403295654000_26.145.170053.11","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000091"},{"key":"2024102403295654000_26.145.170053.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.02.002"},{"key":"2024102403295654000_26.145.170053.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2024102403295654000_26.145.170053.14","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2572"},{"key":"2024102403295654000_26.145.170053.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200209-1112OC"},{"key":"2024102403295654000_26.145.170053.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155108"},{"key":"2024102403295654000_26.145.170053.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1790OC"},{"key":"2024102403295654000_26.145.170053.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005209"},{"key":"2024102403295654000_26.145.170053.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102403295654000_26.145.170053.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102403295654000_26.145.170053.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102403295654000_26.145.170053.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102403295654000_26.145.170053.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00026-2015"},{"key":"2024102403295654000_26.145.170053.24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102403295654000_26.145.170053.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0566OC"},{"key":"2024102403295654000_26.145.170053.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.02.001"},{"key":"2024102403295654000_26.145.170053.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0562OC"},{"key":"2024102403295654000_26.145.170053.28","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2024102403295654000_26.145.170053.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01966-2015"},{"key":"2024102403295654000_26.145.170053.30","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208710"},{"key":"2024102403295654000_26.145.170053.31","unstructured":"National Clinical Guideline Centre (UK) . Diagnosis and Management of Suspected Idiopathic Pulmonary Fibrosis: Idiopathic Pulmonary Fibrosis. London, Royal College of Physicians, 2013."},{"key":"2024102403295654000_26.145.170053.32","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207011"},{"key":"2024102403295654000_26.145.170053.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00584-2015"},{"key":"2024102403295654000_26.145.170053.34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-139"},{"key":"2024102403295654000_26.145.170053.35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12890-016-0308-z","article-title":"Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series","volume":"16","author":"Delanote","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2024102403295654000_26.145.170053.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.03.016","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Karampitsakos","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102403295654000_26.145.170053.37","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0299"},{"key":"2024102403295654000_26.145.170053.38","first-page":"757","article-title":"Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection","volume":"105","author":"Hoshikawa","year":"2004","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"2024102403295654000_26.145.170053.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00028-X"},{"key":"2024102403295654000_26.145.170053.40","unstructured":"Yoshimura K , Miyamoto A , Uruga H , et al. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer. Annual Report by the Study Group of the Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of the Japanese Government 2008 . 2009; pp. 77\u201381."},{"key":"2024102403295654000_26.145.170053.41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir Res"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0053-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:59:59Z","timestamp":1740373199000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0053-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":41,"journal-issue":{"issue":"145","published-online":{"date-parts":[[2017,10,3]]},"published-print":{"date-parts":[[2017,9,30]]}},"alternative-id":["10.1183\/16000617.0053-2017"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0053-2017","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,30]]}}}